Please assess the completion status of the following clinical trial:

Trial Title: How Dose Coenzyme Q10 Supplementation During Infertility Treatment Effects Pregnancy Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Each patient must meet the following criteria:~* Age 38-43 years at the time of enrollment~* Diagnosis of primary infertility~Exclusion Criteria:~* Patients must NOT have any of the following:~* Body mass index (BMI) \> 38 kg/m2~* Early follicular phase (day 2-4) serum FSH level \> 20 mIU/ml.~* Abnormal uterine cavity and /or tubal blockage as evidenced by sonohysterogram or hysterosalpingography~* Any current use of systemic steroid medication within 3 months of study enrollment.~* Any contraindication to being pregnant and carrying a pregnancy to term.~* Contraindication for the use of CoQ10, Menopur, hCG, and Prometrium.~* Any ovarian or abdominal abnormality that may interfere with adequate TVS evaluation.~* Absence of one ovary~* Clinically relevant systemic disease (e.g., Insulin-dependent diabetes, adrenal dysfunction, organic intracranial lesion, hyperprolactinemia, or hypothalamic tumor) or serious illness (Neoplasia).~* History (within past 12 months) or current abuse of alcohol or drugs.~* Administration of any investigational drugs within three months prior to study enrollment.~* Any medical condition that may interfere with the absorption, distribution, metabolism or excretion of the study drugs, gastrointestinal diseases, mal absorption syndromes and liver dysfunction~* Unexplained gynecological bleeding.~* Abnormal sperm quality or semen sample inadequate for IUI preparation (TMC \> 1x106 post wash)~* Patient not able to communicate adequately with the investigators and to comply with the requirements of the entire study.~* Abnormal COH screening bloods for either partner, including: HIV serology, Hepatitis B and C serology, Rubella, and syphilis serology prior to participation in study.~* Unwillingness to give written informed consent.~* The concurrent use of any of the following drugs:~* CoQ10: Daunorubicin, Doxorubicin, Blood Pressure Medications, Warfarin, Timolol, atorvastatin, cerivastatin, lovastatin, pravastatin, simvastatin gemfibrozil, tricyclic antidepressant medications (including amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine).

- Gender: FEMALE
- Minimum Age: 38 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- CoQ10 (Type: EXPERIMENTAL): Coenzyme Q10 co-treatment
- Placebo control (Type: PLACEBO_COMPARATOR): Placebo Co-treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).